EXPERIENCE OF USING A BIOPREPARAT IN THE TREATMENT OF ATOPIC DISEASE WITH DERMATORESPIRATORY SYNDROME

Abstract

The XXI century is designated by the World Health Organization as the “age of allergy”, and the disease itself is designated as an “epidemic”. According to the latest data, 30 % of the European population suffers from allergic diseases, and a significant place among them is occupied by bronchial asthma, allergic rhinitis, atopic dermatitis, and food allergies. Great advances in allergology. advances in the field of molecular biology, the use of omics technologies, have made it possible to significantly improve the diagnosis and treatment of allergic pathology, however, in some patients, despite the therapy received, disease control is not achieved. Complications are formed, the quality of life is reduced, and mortality remains high in patients with bronchial asthma. Changes in the understanding of the pathogenesis of the immune response in allergies have made it possible to develop new approaches to therapy. To date, several biological drugs have been registered in the Russian Federation for the treatment of patients with severe allergic diseases(omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab), which can reduce the severity of clinical manifestations, the frequency of exacerbations of diseases and contribute to a significant improvement in the quality of life of patients. However, treatment with biological drugs is not successful in all patients and should be prescribed in strict accordance with current clinical guidelines, differentiated, strictly individually. The article presents a clinical case of a severe allergic disease with dermatorespiratory syndrome, when the targeted use of the biologic drug dupilumab significantly improved the patient’s condition.